SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease

NCT04269642 on ClinicalTrials.gov · last registry update 2021-04-12

99 participants. Its estimated completion date, 29 September 2021, has passed with no update to the record. Primary outcome, as filed: Change of MDS-UPDRS part 3 score. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is approved in the US, but not for neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: UNKNOWN
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Peptron, Inc.
Sponsor type: Industry
Enrollment: 99
Started: 2020-03-19
Primary completion: 2021-09-29 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change of MDS-UPDRS part 3 score

Conditions studied

Early Parkinson's Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.